Tin tức & Cập nhật

Những điểm chính - Chương trình đào tạo y khoa liên tục: “Tối ưu việc quản lý COVID-19 ở bệnh nhân nguy cơ cao"

09 Nov 2023

Với mong muốn cập nhật lại bức tranh toàn thể về tình hình quản lý COVID-19 trong giai đoạn hiện nay – đặc biệt trên bệnh nhân có nguy cơ cao, vào ngày 20/05/2023 – được sự cho phép của Bộ Y tế –công ty AstraZeneca Việt Nam đã phối hợp với Hội Hô Hấp Việt Nam tổ chức buổi hội thảo khoa học/chương trình đào tạo Y khoa liên tục, dưới cả 2 hình thức trực tiếp và trực tuyến với chủ đề “Tối ưu việc quản lý COVID-19 ở bệnh nhân nguy cơ cao”.

Kính mời quý bác sĩ click vào phần tài liệu đính kèm bên dưới (resources) để xem bài viết chi tiết.

Những điểm chính - Chương trình đào tạo y khoa liên tục: “Tối ưu việc quản lý COVID-19 ở bệnh nhân nguy cơ cao"

09 Nov 2023

LIPI score predicts survival in NSCLC patients treated with PD-1/PD-L1 inhibitor plus chemo

08 Nov 2023

Use of the lung immune prognostic index (LIPI) score can help predict the efficacy of combination therapy of programmed cell death (PD)-1/PD-ligand 1 (PD-L1) blockade and chemotherapy (CT) in patients with advanced nonsmall cell lung cancer (NSCLC), suggests a study.

LIPI score predicts survival in NSCLC patients treated with PD-1/PD-L1 inhibitor plus chemo

08 Nov 2023

Neoadjuvant immunotherapy delivers better response in NSCLC

08 Nov 2023 bởi

Patients with nonsmall cell lung cancer (NSCLC) who have been treated with neoadjuvant immunotherapy show greater response than those treated with neoadjuvant chemotherapy (CT), as shown in a study. Treatment-related adverse events (TRAEs) are similar between the two groups.

Neoadjuvant immunotherapy delivers better response in NSCLC

08 Nov 2023

Original New Drug Application Approvals by US FDA (16-31 October 2023)

08 Nov 2023

New drug applications approved by US FDA as of 16-31 October 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 October 2023)

08 Nov 2023

Amivantamab-lazertinib bests osimertinib in head-to-head trial on lung cancer

08 Nov 2023 bởi

In the phase III MARIPOSA trial, the amivantamab-lazertinib cocktail outdid osimertinib as first-line (1L) treatment for EGFR-mutated, advanced non-small cell lung cancer (NSCLC).

Amivantamab-lazertinib bests osimertinib in head-to-head trial on lung cancer

08 Nov 2023

Depression severity tied to respiratory symptoms

05 Nov 2023

Depression levels among adults appear to be positively associated with respiratory symptoms, asthma, and chronic obstructive pulmonary disease (COPD), according to a study.

Depression severity tied to respiratory symptoms

05 Nov 2023

Higher nasal CPAP helps avoid extubation failure in extremely preterm infants

02 Nov 2023

Extubation with higher levels of nasal continuous positive airway pressure (nCPAP) in preterm infants leads to a lower incidence of extubation failure compared with standard nCPAP levels, without compromising safety, according to a study.

Higher nasal CPAP helps avoid extubation failure in extremely preterm infants

02 Nov 2023

Ritonavir-boosted nirmatrelvir protects older adults against post-COVID conditions

26 Oct 2023 bởi

Treatment with nirmatrelvir/ritonavir helps lower the incidence of post-COVID conditions (PCC) in older adults, according to a large study.

Ritonavir-boosted nirmatrelvir protects older adults against post-COVID conditions

26 Oct 2023

Older age, comorbidities drivers of hospitalization for RSV

25 Oct 2023 bởi

Advanced age (≥65 years) and comorbidities increase the risk of respiratory syncytial virus (RSV)-associated hospitalization, according to a presentation at IDWeek 2023.

Older age, comorbidities drivers of hospitalization for RSV

25 Oct 2023

Supranormal FEV1, FVC values linked to better lung function

21 Oct 2023

Nearly 3 percent of the general population demonstrate greater-than-expected values of forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC), which are both indicative of a better lung function, according to a recent study in Austria.

Supranormal FEV1, FVC values linked to better lung function

21 Oct 2023

Tin tức & Cập nhật

Lọc theo Chuyên ngành:

Chuyên ngành:

Những điểm chính - Chương trình đào tạo y khoa liên tục: “Tối ưu việc quản lý COVID-19 ở bệnh nhân nguy cơ cao"

Những điểm chính - Chương trình đào tạo y khoa liên tục: “Tối ưu việc quản lý COVID-19 ở bệnh nhân nguy cơ cao"

LIPI score predicts survival in NSCLC patients treated with PD-1/PD-L1 inhibitor plus chemo

LIPI score predicts survival in NSCLC patients treated with PD-1/PD-L1 inhibitor plus chemo

Neoadjuvant immunotherapy delivers better response in NSCLC

Neoadjuvant immunotherapy delivers better response in NSCLC

Original New Drug Application Approvals by US FDA (16-31 October 2023)

Original New Drug Application Approvals by US FDA (16-31 October 2023)

Amivantamab-lazertinib bests osimertinib in head-to-head trial on lung cancer

Amivantamab-lazertinib bests osimertinib in head-to-head trial on lung cancer

Depression severity tied to respiratory symptoms

Depression severity tied to respiratory symptoms

Higher nasal CPAP helps avoid extubation failure in extremely preterm infants

Higher nasal CPAP helps avoid extubation failure in extremely preterm infants

Ritonavir-boosted nirmatrelvir protects older adults against post-COVID conditions

Ritonavir-boosted nirmatrelvir protects older adults against post-COVID conditions

Older age, comorbidities drivers of hospitalization for RSV

Older age, comorbidities drivers of hospitalization for RSV

Supranormal FEV1, FVC values linked to better lung function

Supranormal FEV1, FVC values linked to better lung function